RxDoctor Payments Data

Derrick Butler

Family Medicine · Los Angeles, CANPI 1366487225

Payments from drug & device makers

$691,736in general payments, 2019–2025

Across 947 payments — averaging $730.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$442K
  • Gilead$178K
  • Janssen Products, LP$54K
  • Viiv Healthcare Company$16K
  • Theratechnologies Inc.$750
  • Johnson & Johnson$312
  • plus $1K from 10 others

What the payments were for

  • Consulting fees$20,2253%
  • Speaking & faculty fees$517,86475%
  • Travel & lodging$130,80219%
  • Food & beverage$22,7193%
  • Education$1260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$691,736 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala94$363,129
DovatoDolutegravir Sodium/Lamivudine91$261,109
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf47$215,290
OdefseyEmtricitab/Rilpiviri/Tenof Ala28$96,869
TivicayDolutegravir Sodium32$69,182
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$45,773
PrezcobixDarunavir/Cobicistat13$30,961
OzempicSemaglutide27$24,280
Maraviroc12$15,409
EliquisApixaban13$11,260
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$10,833
Atrovent HfaIpratropium Bromide11$5,819
Breo ElliptaFluticasone/Vilanterol14$5,562
Spiriva HandihalerTiotropium Bromide11$5,517
LumiganBimatoprost19$5,215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$177,694$408,902107 claims
Viiv Healthcare CompanyDovato, Tivicay$16,110$330,291123 claims
Janssen Products, LPSymtuza$54,246$215,29047 claims
Johnson & JohnsonPrezcobix$312$30,96113 claims
Novo NordiskOzempic$246$24,28027 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$441,554$19,35743 claims
AbbVieLumigan$160$5,21519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →